Hyperliquid Labs is in advanced talks with Payward, the parent company of crypto exchange Kraken, about bringing its perpetual futures to U.S. traders. A deal would require regulatory sign-off before any launch.
What's on the table
Perpetual futures are a type of derivative that lets traders bet on the price of an asset without an expiry date. They've become a staple in crypto markets, offering leverage and round-the-clock trading. Hyperliquid Labs runs a platform built around these contracts, and a partnership with Kraken would give it a direct route into the U.S. market.
The talks are at an advanced stage, but no agreement has been finalized. Neither company has publicly commented on the discussions. If completed, the deal would mark a significant step for Hyperliquid, which has so far focused on markets outside the U.S.
The regulatory hurdle
U.S. regulators have been cautious about crypto derivatives, and any product offered to American traders would need approval from agencies like the Commodity Futures Trading Commission. That process can be lengthy and uncertain. The fact that the talks are described as advanced suggests both sides see a path forward, but the regulatory piece remains the biggest unknown.
Kraken, one of the largest U.S. crypto exchanges, already operates in a heavily regulated environment. Its parent company, Payward, would likely need to ensure any new offering meets federal standards. That could mean additional licensing or structural changes to how the product is offered.
Why Kraken
For Kraken, adding Hyperliquid's perpetual futures could broaden its derivatives lineup and attract traders who currently go elsewhere for these products. For Hyperliquid, the deal would open up the U.S. market, which has been largely off-limits due to regulatory complexity.
The two companies have complementary strengths. Kraken brings a U.S. customer base and regulatory experience; Hyperliquid brings a trading platform that has gained traction among crypto derivatives users. But the deal is not done, and the regulatory approval process could reshape the terms.
The talks are ongoing, and there's no confirmed timeline for a decision. The key question is whether U.S. regulators will sign off on the arrangement, and what conditions they might attach. Until that's resolved, the deal remains in limbo.
